Abstracts tagged "Early Rheumatoid Arthritis"

Abstract Number: 2503 • 2014 ACR/ARHP Annual Meeting
Early Response to Full-Dose Etanercept-Plus-Methotrexate Induction Therapy Predicts Sustained Remission with Reduced-Dose Combination Therapy in Early Rheumatoid Arthritis Patients
Paul Emery¹, Ronald Pedersen², Jack Bukowski³ and Lisa Marshall⁴, ¹NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds., United Kingdom, Leeds, United Kingdom, ²Specialty Care, Pfizer Inc, Collegeville, PA, ³Department of Specialty Care, Pfizer Inc, Collegeville, PA, ⁴Inflammation Immunology Disease Group, Pfizer Inc., Collegeville, PA
Background/Purpose: In early rheumatoid arthritis (RA), achievement of clinical remission and low disease activity (LDA) limits joint damage and disability.1 Anti-TNF agents are effective in…
Abstract Number: 1527 • 2014 ACR/ARHP Annual Meeting
Efficacy of Biologic Treatments in Early Active Rheumatoid Arthritis: An Indirect Comparison
Laura Sawyer¹, Stacey Chang¹, Alex Diamantopoulos² and Fred Dejonckheere³, ¹Symmetron Limited, London, United Kingdom, ²Symmetron Limited, Herts, United Kingdom, ³F. Hoffmann-La Roche, Basel, Switzerland
Background/Purpose: To date, no head-to-head trials have been conducted comparing the efficacy of biologic treatments for early active rheumatoid arthritis (ERA). Here, we evaluated the…
Abstract Number: 392 • 2014 ACR/ARHP Annual Meeting
Neuroendocrine Hormone and Metabolic Peptide Levels in the Earliest Phases of Rheumatoid Arthritis – Do Free Fatty Acids Play a Role?
Man Wai Tang¹, Frieda A. Koopman², Jan P.M. Visscher², Marjolein J.H. de Hair², Danielle M. Gerlag^2,3 and Paul P. Tak^2,4, ¹Division of Clinical Immunology and Rheumatology & Department of Experimental Immunology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, ²Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ³GlaxoSmithKline, Cambridge, United Kingdom, ⁴University of Cambridge, Cambridge and GlaxoSmithKline, Stevenage, United Kingdom
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease associated with several neuroendocrine hormones and metabolic peptides. The crosstalk between the hormones and the immune…
Abstract Number: 2485 • 2014 ACR/ARHP Annual Meeting
Predictors of Drug-Free Remission Following Treatment with Abatacept (in Combination with Methotrexate or as Monotherapy) in Early Rheumatoid Arthritis
P Emery¹, Gerd Burmester², Vivian P. Bykerk³, B Combe⁴, Daniel E. Furst⁵, E Barre⁶, C S Karyekar⁷, D Wong⁷ and T W J Huizinga⁸, ¹University of Leeds, Leeds, United Kingdom, ²Charité – University Medicine Berlin, Berlin, Germany, ³Hospital for Special Surgery, Weill Cornell Medical College, New York, NY, ⁴Monpellier University Hospital, Montpellier, France, ⁵University of California at Los Angeles, Los Angeles, CA, ⁶Bristol-Myers Squibb, Braine-L’Alleud, Belgium, ⁷Bristol-Myers Squibb, Princeton, NJ, ⁸Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: In the Phase IIIb, randomized, double-blind, active-controlled AVERT study, abatacept (ABA) + MTX and ABA monotherapy induced protocol-defined DAS remission (DAS28 [CRP]
Abstract Number: 1521 • 2014 ACR/ARHP Annual Meeting
Sustained Improvements in Magnetic Resonance Imaging Outcomes with Abatacept Following the Withdrawal of All Treatment in Patients with Early Rheumatoid Arthritis
C Peterfy¹, Gerd Burmester², Vivian P. Bykerk³, B G Combe⁴, J C DiCarlo¹, Daniel E. Furst⁵, T W J Huizinga⁶, C S Karyekar⁷, D Wong⁷, Philip G. Conaghan⁸ and P Emery⁹, ¹Spire Sciences, Inc., Boca Raton, FL, ²Charité – University Medicine Berlin, Berlin, Germany, ³Hospital for Special Surgery, Weill Cornell Medical College, New York, NY, ⁴Hôpital Lapeyronie, Montpellier, France, ⁵University of California at Los Angeles, Los Angeles, CA, ⁶Leiden University Medical Center, Leiden, Netherlands, ⁷Bristol-Myers Squibb, Princeton, NJ, ⁸NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁹University of Leeds, Leeds, United Kingdom
Background/Purpose: Biologic treatment can lead to improved clinical outcomes in early RA. In the Assessing Very Early Rheumatoid arthritis Treatment (AVERT) study, abatacept (ABA) +…
Abstract Number: 388 • 2014 ACR/ARHP Annual Meeting
Soluble TREM-1 Is a Biomarker of Anti-CCP-Positive, DMARD-Naive Early Rheumatoid Arthritis
Shachaf Ofer-Shiber¹, Elisheva Pokroy-Shapira², Yair Molad^3,4, Shirly Oren², Hagit Shay-Aharoni² and Ilan Babai⁵, ¹Department of Internal Medicine H, Rabin Medical Center, Beilinson Hospital and Sackler Faculty of Medicine, Tel Aviv University, Petach Tikva, Israel, ²Rheumatology Unit, Rabin Medical Center, Beilinson Hospital and Sackler Faculty of Medicine, Tel Aviv University, Petach Tikva, Israel, ³Rheumatology Unit, Rabin Medical Center, Beilinson Hospital and Sackler Faculty of Medicine, Tel Aviv University, Petah Teqva, Israel, ⁴Laboratory of Inflammation Research, Felsenstein Medical Research Center, Sackler Faculty of Medicine, Tel Aviv University, Petach Tikva, Israel, ⁵Laboratory of Clinical Immunology, Rabin Medical Center, Beilinson Hospital, Petach Tikva, Israel
Background/Purpose : Triggering receptor expressed on myeloid cells-1 (TREM-1) is a cell-surface receptor, expressed mainly on monocytes and neutrophils and involved in amplification of the inflammatory…
Abstract Number: 2472 • 2014 ACR/ARHP Annual Meeting
The First, Multicenter, Double-Blind, Randomized, Parallel-Group Study of Certolizumab Pegol in Early Rheumatoid Arthritis Demonstrates Inhibition of Joint Damage Progression
Tatsuya Atsumi¹, Kazuhiko Yamamoto², Tsutomu Takeuchi³, Hisashi Yamanaka⁴, Naoki Ishiguro⁵, Yoshiya Tanaka⁶, Katsumi Eguchi⁷, Akira Watanabe⁸, Hideki Origasa⁹, Toshiharu Shoji¹⁰, Osamu Togo¹¹, Toshiyuki Okada¹², Désirée M. van der Heijde¹³, Nobuyuki Miyasaka¹⁴ and Takao Koike^15,16, ¹Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan, ²Department of Allergy and Rheumatology, The University of Tokyo, Tokyo, Japan, ³Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Kitakyushu, Japan, ⁴Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ⁵Department of orthopedics, Nagoya University Graduate School and Faculty of Medicine, Nagoya, Japan, ⁶The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ⁷Department of Rheumatology, Sasebo City General Hospital, Nagasaki, Japan, ⁸Division of Rheumatology, Department of Internal Medicine, School of Medicine, Tohoku University, Tokyo, Japan, ⁹Division of Biostatistics and Clinical Epidemiology, University of Toyama School of Medicine, Toyama, Japan, ¹⁰Department of Clinical Research and Development, UCB Pharma, Tokyo, Japan, ¹¹Biometrics Group, UCB Pharma, Tokyo, Japan, ¹²Astellas Pharma Inc, Tokyo, Japan, ¹³Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ¹⁴Department of Rheumatology, Tokyo Medical and Dental University, Tokyo, Japan, ¹⁵NTT Sapporo Medical Center, Sapporo, Japan, ¹⁶Hokkaido University Graduate School of Medicine, Sapporo, Japan
Background/Purpose The efficacy and safety of certolizumab pegol (CZP)+methotrexate (MTX) therapy compared to MTX alone, in Japanese MTX-naïve early rheumatoid arthritis (RA) patients (pts) with…
Abstract Number: 1411 • 2014 ACR/ARHP Annual Meeting
Psychological Distress over Time in Early Rheumatoid Arthritis: Results from a Longitudinal Study in an Early Arthritis Cohort
Bernard Combe¹, Nathalie Rincheval², René-Marc Flipo³, Philipe M. Goupille⁴, Jean-Pierre Daurès² and JP Boulenger⁵, ¹Immuno-Rhumatologie, Hôpital Lapeyronie, Montpellier, France, ²Institut Universitaire de Recherche Clinique, Montpellier, France, ³Rheumatology, Hopital R Salengro CHRU, Lille CEDEX, France, ⁴Rheumatology, Hopital Trousseau, Tours, France, ⁵CHRU Montpellier I University, La Colombiere Hospital, Montpellier, France
Background/Purpose Rheumatoid arthritis (RA) is a chronic disease with frequent psychological comorbidities, of which depression and anxiety are 2 common manifestations. We aimed to identify…
Abstract Number: 362 • 2014 ACR/ARHP Annual Meeting
14-3-3η Early RA Biomarkers: Does Seronegative RA Exist?
Dirkjan van Schaardenburg¹, Walter P. Maksymowych², Maarten Boers³, Samina Turk⁴, Mairead Murphy⁵ and Anthony Marotta⁶, ¹Dr Jan van Breemenstraat 2, Reade, Amsterdam, Netherlands, ²Department of Medicine, University of Alberta, Edmonton, AB, Canada, ³Deapartment of Epidemiology and Biostatistics, Jan van Breemen Research Institute/Reade, Amsterdam, Netherlands, ⁴Reade, Amsterdam, Netherlands, ⁵Augurex Life Sciences Corp., North Vancouver, BC, Canada, ⁶1423 Dempsey Road, Augurex Life Sciences Corp., North Vancouver, BC, Canada
Background/Purpose RF and ACPA are used for early diagnosis and in prediction models for the risk of RA development in arthralgia patients. There remains a…
Abstract Number: 2460 • 2014 ACR/ARHP Annual Meeting
Phospho-STAT1/3 and Gene Expression Measurement in Circulating CD4⁺ T Cells As Diagnostic Tools in Early Autoantibody-Negative Rheumatoid Arthritis
Amy E. Anderson¹, Arthur G Pratt¹, Mamdouh Sedhom², Nisha Nair³, Jonathan Massey³, Christine Routledge¹, Ben Hargreaves¹, Philip Brown¹, Anne Barton⁴, John D Isaacs¹ and Ranjeny Thomas², ¹Institute of Cellular Medicine (Musculoskeletal Research Group), NIHR Newcastle Biomedical Research Centre, Newcastle Hospitals Foundation Trust and Newcastle University, Newcastle upon Tyne, United Kingdom, ²Translational Research Institute, The University of Queensland Diamantina Institute, Queensland, Australia, ³NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester Academy of Health Sciences, Manchester, United Kingdom, ⁴NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester Academic Health Science Centre, Manchester, United Kingdom
Background/Purpose Early diagnosis of rheumatoid arthritis (RA) improves outcomes but is challenging, particularly amongst anti-citrullinated peptide auto-antibody (ACPA) negative individuals. Previously we identified an IL-6…
Abstract Number: 1402 • 2014 ACR/ARHP Annual Meeting
Parameters of Periodontitis Correlate with Anti-Citrullinated Protein Antibodies and P. Gingivalis Antibody Titers in Patients with Early or Chronic Rheumatoid Arthritis
Sheila L. Arvikar¹, Hatice Hasturk², Marcy B. Bolster^3,4, Deborah S. Collier⁵, Alpdogan Kantarci² and Allen C. Steere⁶, ¹Rheumatology, Allergy & Immunology, Massachusetts General Hospital, Boston, MA, ²Department of Applied Oral Health Sciences, Forsyth Institute, Cambridge, MA, ³Medicine, Massachussetts General Hospital, Boston, MA, ⁴Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, MA, ⁵Rheumatology, Massachusetts General Hospital, Boston, MA, ⁶Medicine, Center for Immunolgy and Inflammatory Diseases, Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose Emerging evidence suggests that periodontitis and periodontal pathogens, such as Porphyromonas gingivalis (Pg), may be an environmental trigger for rheumatoid arthritis (RA). We found…
Abstract Number: 361 • 2014 ACR/ARHP Annual Meeting
Citrullinated 14-3-3η Antibodies Are Specific for Early and Established RA and Are Complementary to ACPA
Anthony Marotta¹, Dirkjan van Schaardenburg², Gilles Boire³, Désirée van der Heijde⁴, Robert Landewé⁵, Maarten Boers⁶, C.F. Allaart⁷, Mairead Murphy⁸, Samina Turk⁹, Vivian P. Bykerk¹⁰, Edward Keystone¹¹, Katherine A. Siminovitch¹¹ and Walter P. Maksymowych¹², ¹1423 Dempsey Road, Augurex Life Sciences Corp., North Vancouver, BC, Canada, ²Dr Jan van Breemenstraat 2, Reade, Amsterdam, Netherlands, ³Rheumatology Division, CHUS - Sherbrooke University, Sherbrooke, QC, Canada, ⁴Leiden University Medical Center, Leiden, Netherlands, ⁵Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ⁶Deapartment of Epidemiology and Biostatistics, Jan van Breemen Research Institute/Reade, Amsterdam, Netherlands, ⁷Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁸Augurex Life Sciences Corp., North Vancouver, BC, Canada, ⁹Reade, Amsterdam, Netherlands, ¹⁰Divison of Rheumatology, Hospital for Special Surgery, New York, NY, ¹¹Mount Sinai Hospital, Toronto, ON, Canada, ¹²Department of Medicine, University of Alberta, Edmonton, AB, Canada
Background/Purpose Citrullination is a post-translational modification whereby arginine (Arg) is deiminated by PAD enzymes to form citrulline (Cit). In RA, current ACPA assays measure the…
Abstract Number: 2463 • 2014 ACR/ARHP Annual Meeting
Stromal Cell Markers Are Differentially Expressed in the Synovial Tissue of Patients with Early Arthritis
Ivy Y.K. Choi¹, Olga N. Karpus², Jason D. Turner³, Debbie L. Hardie³, Maria J. H. de Hair¹, Karen I. Maijer¹, Paul-Peter Tak^1,4,5, Karim Raza^3,6, Jörg Hamann², Christopher Buckley³, Danielle Marie Gerlag^1,7 and Andrew Filer^3,8, ¹Division of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ²Department of Experimental Immunology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ³Rheumatology Research Group, MRC Centre for Immune Regulation, School of Immunity and Infection, University of Birmingham, Birmingham, United Kingdom, ⁴GlaxoSmithKline, Stevenage, United Kingdom, ⁵University of Cambridge, Cambridge, United Kingdom, ⁶Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, United Kingdom, ⁷GlaxoSmithKline, Cambridge, United Kingdom, ⁸University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom
Background/Purpose Previous studies have shown increased expression of stromal markers in synovial tissue (ST) of patients with established rheumatoid arthritis (RA). Here, the expression of…
Abstract Number: 1388 • 2014 ACR/ARHP Annual Meeting
Prevalence and Predictive Factors of Drug-Free and Sustained Remission in Patients with Early Arthritis
Margarita Landi¹, Christian A. Waimann², Gustavo Citera³, O Cerda⁴, Federico Ceccatto⁵, Sergio Paira⁶, Francisco Caeiro⁷, Lucila Marino⁸, M Mamani⁹, Anastasia Secco⁹, G Crespo⁹, AC Alvarez¹⁰, Maria Haye Salinas⁷, A Alvarellos¹¹, Javier Rosa¹², Valeria Scaglioni¹³, Enrique R. Soriano¹⁴, Josefina Marcos¹⁵, Mercedes García¹⁵, A Salas¹⁵, Alejandro Martinez¹⁶, Rafael Chaparro del Moral¹⁷, Oscar Luis Rillo¹⁷, Horacio Berman¹⁸, Alberto Berman¹⁸, Francisco Colombres¹⁸, Edson Veloso¹⁹, Ricardo V. Juárez²⁰, Maria Elena Crespo²¹, Ana Quinteros²², M Leal²², Gabriela Salvatierra²³, C Ledesma²³, Mónica P. Sacnun²⁴, R Quintana²⁵ and Marcelo Abdala²⁶, ¹Rheumatology, Instituto Rehabilitacion Psicofisica, Buenos Aires, Argentina, ²Rheumatology, Hospital Olavarria, Olavarria, Argentina, ³Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ⁴Rheumatology, Instituto de Rehabilitacion Psicofisica, Buenos Aires, Argentina, ⁵Rheumatology, Hospital Jose María Cullen, Santa Fé, Argentina, ⁶Section of Rheumatology, Hospital Jose Maria Cullen, Santa Fe, Argentina, ⁷Reumatología, Hospital Privado de Córdoba, Córdoba, Argentina, ⁸Rheumathology, Hospital Bernardino Rivadavia, Buenos Aires, Argentina, ⁹Rheumatology, Hospital Bernardino Rivadavia, Buenos Aires, Argentina, ¹⁰Hospital Privado Centro Médico de, Córdoba, Argentina, ¹¹Rheumatology, Hospital Privado Centro Medico De Córdoba, Cordoba, Argentina, ¹²Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ¹³Rheumatology Unit, Internal Medical Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Buenos Aires, Argentina, ¹⁴Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Buenos Aires, Argentina, ¹⁵HIGA San Martín, La Plata, Argentina, ¹⁶Rheumatology Unit, Hospital General de Agudos Dr. E. Tornú, Buenos Aires, Argentina, ¹⁷Rheumatology Section, Hospital General de Agudos Dr. E. Tornú, Buenos Aires, Argentina, ¹⁸Centro Medico Privado de Reumatologia, Tucumán, Argentina, ¹⁹Sanatorio y Universidad Adventista Del Plata, Entre Rios, Argentina, ²⁰Rheumatology Section, Hospital Señor del Milagro, Salta, Argentina, ²¹Hospital Señor Del Milagro, Salta, Argentina, ²²Centro Integral de Reumatología, Tucumán, Argentina, ²³Instituto Provincial De Rehabilitación Integral, Stgo. del Estero, Argentina, ²⁴Hospital Provincial, Rosario, Argentina, ²⁵Hospital provincial, Rosario, Argentina, ²⁶Hospital Provincial del Centenario, Santa Fe, Argentina
Background/Purpose : Early and sustained remission has become the ultimate goal in early arthritis patients. The aim of our study was to estimate the prevalence…
Abstract Number: 360 • 2014 ACR/ARHP Annual Meeting
88% of Recent Onset Polyarthritis Patients Are Positive for 14-3-3η Markers and 14-3-3η Auto-Antibodies Inform a Favourable Prognosis
Gilles Boire¹, Nathalie Carrier², Artur Jose de Brum-Fernandes³, Patrick Liang⁴, Ariel Masetto⁵, Yuan Gui⁶, Mairead Murphy⁶, Walter P. Maksymowych⁷ and Anthony Marotta⁸, ¹Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada, ²Rheumatology, Universite de Sherbrooke, Sherbrooke, QC, Canada, ³Department of Medicine, Universite de Sherbrooke, Sherbrooke, QC, Canada, ⁴Rheumatology Division, CHUS, Sherbrooke, QC, Canada, ⁵Rheumatology, CHUS, Fleurimont, QC, Canada, ⁶Augurex Life Sciences Corp., North Vancouver, BC, Canada, ⁷Department of Medicine, University of Alberta, Edmonton, AB, Canada, ⁸1423 Dempsey Road, Augurex Life Sciences Corp., North Vancouver, BC, Canada
Background/Purpose The 14-3-3η protein has been described as a mechanistic marker that is detectable in serum during the very early stages of RA development. A…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.